ReviewJournal of personalized medicine2021
Current Omics Trends in Personalised Head and Neck Cancer Chemoradiotherapy.
Review in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Pooled it
- Biologically Individualized Radiotherapy Based on PET: A Novel Approach to Treatment Optimization of Head and Neck Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Advancements in Image-Based Artificial Intelligence in the Diagnosis and Treatment of Head and Neck Squamous Cell Carcinoma: A Narrative Review.International journal of general medicine · 2026Review
- Article
- Article
- Radiomics for therapy-specific head and neck squamous cell carcinoma survival prognostication (part I).BMC medical imaging · 2023Article
- Current Role of Delta Radiomics in Head and Neck Oncology.International journal of molecular sciences · 2023Review
- Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.Journal of personalized medicine · 2022Review
- ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma.Journal of clinical laboratory analysis · 2022Article
- Current Challenges in Head and Neck Cancer Management.Cancers · 2022Article
- Prognostic Factors for the Therapeutic Performance of Cisplatin in Head and Neck Malignancies.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoradiotherapy remains the most common management of locally advanced head and neck cancer. While both treatment components have greatly developed over the years, the quality of life and long-term survival of patients undergoing treatment for head and neck malignancies are still poor. Research in head and neck oncology is equally focused on the improvement of tumour response to treatment and on the limitation of normal tissue toxicity. In this regard, personalised therapy through a multi-omics approach targeting patient management from diagnosis to treatment shows promising results. The aim of this paper is to discuss the latest results regarding the personalised approach to chemoradiotherapy of head and neck cancer by gathering the findings of the newest omics, involving radiotherapy (dosiomics), chemotherapy (pharmacomics), and medical imaging for treatment monitoring (radiomics). The incorporation of these omics into head and neck cancer management offers multiple viewpoints to treatment that represent the foundation of personalised therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.